Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

25 sierpnia 2017 zaktualizowane przez: Celgene

A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

488

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Australia
      • Fitzroy, Australia, 3065
        • St Vincent's Hospital
    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
    • Victoria
      • East Melbourne, Victoria, Australia, 3002
        • Peter MacCallum Cancer Centre
      • Footscray, Victoria, Australia, 3011
        • Western Hospital
      • Melbourne, Victoria, Australia, 3050
        • Royal Melbourne Hospital
  • Austria
      • Salzburg, Austria, 5020
        • Landeskliniken Salzburg Saint Johanns-Spital, III Medizinische Abteilung
    • Upper Austria
      • Wels, Upper Austria, Austria, 4600
        • Klinikum Wels-Grieskirchen GmbH
    • Vienna
      • Wien, Vienna, Austria, 1160
        • Wilhelminenspital, I Medizinische Abt.
  • Belgia
      • La Louvière, Belgia, 7100
        • Centre Hospitalier de Jolimont-Lobbes
    • Hainaut
      • Charleroi, Hainaut, Belgia, 6000
        • Grand Hôpital de Charleroi
    • Namur
      • Yvoir, Namur, Belgia, 5530
        • Cliniques Universitaires UCL de Mont-Godinne
    • Oost-vlaanderen
      • Ghent, Oost-vlaanderen, Belgia, 9000
        • Universitair Ziekenhuis Gent
    • West-vlaanderen
      • Brugge, West-vlaanderen, Belgia, 8000
        • Algemeen Ziekenhuis Sint-Jan
  • Chiny
      • Beijing, Chiny, 100730
        • Peking Union Medical College Hospital
      • Beijing, Chiny, 100083
        • The Third Hospital of Peking University
      • Jiangsu, Chiny, 210029
        • Peoples Hospital of Jiangsu Province
      • Shanghai, Chiny, 200025
        • Shanghai Ruijin Hospital
      • Shanghai, Chiny, 200433
        • Shanghai Changhai Hospital,the Second Military Medical University
      • Sichuan, Chiny, 610041
        • West China Hospital,Sichuan University
      • Tianjin, Chiny, 3000200
        • Tianjin Blood Disease Hospital
  • Czechy
    • Jihormoravsky Kraj
      • Brno, Jihormoravsky Kraj, Czechy, 625 00
        • Fakultní nemocnice Brno
    • Olomoucký Kraj
      • Olomouc, Olomoucký Kraj, Czechy, 775 20
        • Fakultni nemocnice Olomouc, Hemato-onkologicka klinika
    • Praha
      • Praha 2, Praha, Czechy, 128 08
        • Vseobecna fakultni nemocnice v Praze
      • Praha 2, Praha, Czechy, 128 20
        • Ustav Hematologie A Krevni Transfuze
  • Federacja Rosyjska
      • Ekaterinburg, Federacja Rosyjska, 620137
        • Central city hospital # 7
      • Moscow, Federacja Rosyjska, 125284
        • City Clinical Hospital n.a. S. P. Botkin
      • Nizhniy Novgorod, Federacja Rosyjska, 603126
        • State Healthcare Institution "Nizhny Novgorod N.A. Semashko Regional Clinical Hospital"
      • Saint Petersburg, Federacja Rosyjska, 197089
        • Saint Petersburg State Academician I.P. Pavlov Medical University
      • Saratov, Federacja Rosyjska, 410 028
        • Saratov State Medical University
  • Francja
      • Aquitaine, Francja, 64109
        • Centre Hospitalier de la Cote Basque
      • Lyon Cedex 03, Francja, 69437
        • Centre Hospitalier Universitaire de Lyon-Hôpital Edouard Herriot
    • Alsace
      • Strasbourg, Alsace, Francja, 67091
        • Centre Hospitalier Régional Universitaire, Hôpital de Hautepierre
    • ILE-DE-France
      • Bobigny, ILE-DE-France, Francja, 93009
        • Hospital Avicenne, Service d'hematologie Clinique
    • Ile-de-france
      • Clamart Cedex, Ile-de-france, Francja, 92141
        • Hopital Percy Clamart
      • Paris Cedex 10, Ile-de-france, Francja, 75475
        • Hopital Saint Louis
    • Limousin Lorraine
      • Limoges, Limousin Lorraine, Francja, 87042
        • Centre Hopitalier Universitaire Dupuytren
    • Midi-pyrénées
      • Toulouse Cedex 09, Midi-pyrénées, Francja, 31059
        • Centre Hospitalier Universitaire de Toulouse
    • Nice
      • Nice Cedex 3, Nice, Francja, 06202
        • Centre Hospitalier Universitaire de Nice
    • Pays de La Loire
      • Angers cedex 09, Pays de La Loire, Francja, 49933
        • CHRU d'Angers
      • Nantes Cedex 1, Pays de La Loire, Francja, 44093
        • Centre Hospitalier Universitaire Nantes, Hotel Dieu
    • Picardie
      • Amiens Cedex 1, Picardie, Francja, 80054
        • Centre Hospitalier Universitaire d'Amiens, Groupe Hospitalier Sud
    • Provence Alpes Cote D'azur
      • Marseille, Provence Alpes Cote D'azur, Francja, 13385
        • Hôpital de la Conception
  • Hiszpania
      • Barcelona, Hiszpania, 08036
        • Hospital Clinic i Provincial de Barcelona
      • Madrid, Hiszpania, 28009
        • Hospital General Universitario Gregorio Marañon
      • Salamanca, Hiszpania, 37007
        • Hospital Universitario de Salamanca
      • Sevilla, Hiszpania, 41013
        • Hospital Universitario Virgen del Rocio
      • Valencia, Hiszpania, 46009
        • Hospital Universitario La Fe
    • Asturias
      • Oviedo, Asturias, Hiszpania, 33006
        • Hospital Central de Asturias
    • Baleares
      • Palma de Mallorca, Baleares, Hiszpania, 07198
        • Hospital Son Llatzer
      • Palma de Mallorca, Baleares, Hiszpania, 07014
        • Hospital Son Dureta
  • Holandia
      • Groningen, Holandia, 9700 RB
        • Universitair Medisch Centrum Groningen
  • Izrael
      • Beer Yaakov, Izrael, 70300
        • Assaf Harofeh Medical Centre
      • Jerusalem, Izrael, 91120
        • Hadassah Medical Center
      • Jerusalem, Izrael, 91031
        • Shaare Zedek Medical Center
      • Petach Tikva, Izrael, 49100
        • Rabin Medical Center
      • Tel Aviv, Izrael, 64239
        • Sourasky Medical Center
      • Tel Hashomer, Izrael, 52621
        • Chaim Sheba Medical Center - Tel Hashomer, Heart Institute
    • Beersheva
      • Beer Sheva, Beersheva, Izrael, 84101
        • Soroka Medical Center
  • Kanada
      • Calgary, Kanada, T2N 2T9
        • Tom Baker Cancer Centre
      • Ontario, Kanada, M5G 2M9
        • Princess Margaret Hospital
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • University of Alberta Hospital
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3E 0V9
        • Cancer Care Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • Queen Elizabeth II Health Sciences Centre
    • Ontario
      • Ottawa, Ontario, Kanada, K1H8L6
        • Ottawa Hospital General Campus
      • Toronto, Ontario, Kanada, M4N 3M5
        • Sunnybrook Odette Cancer Centre
    • Quebec
      • Montreal, Quebec, Kanada, H1T 2M4
        • Hôpital Maisonneuve-Rosemont
      • Montreal, Quebec, Kanada, H4J 1C5
        • Hopital Du Sacre Coeur de Montreal
      • Montreal, Quebec, Kanada, H2L 4M1
        • Centre Hospitalier de l'Université de Montréal pavilion Notre Dame
  • Niemcy
    • Baden-wuerttemberg
      • Heidelberg, Baden-wuerttemberg, Niemcy, 69120
        • Universitätsklinikum Heidelberg
      • Ulm, Baden-wuerttemberg, Niemcy, 89081
        • Universitätsklinikum Ulm
    • Mecklenburg-vorpommern
      • Rostock, Mecklenburg-vorpommern, Niemcy, 18057
        • University of Rostock, Div. of Haematology and Oncology
    • Nordrhein-Westfallen
      • Essen, Nordrhein-Westfallen, Niemcy, 45122
        • Universitatsklinikum Essen, Zentrum fur Tumorforschung und Tumortherapie
    • Nordrhein-westfalen
      • Düesseldorf, Nordrhein-westfalen, Niemcy, 40211
        • Heinrich-Heine-Universität Düsseldorf
    • Sachsen
      • Leipzig, Sachsen, Niemcy, 04103
        • Universitätsklinikum Leipzig
    • Thueringen
      • Jena, Thueringen, Niemcy, 07747
        • Universitätsklinikum Jena
  • Polska
    • Dolnoslaskie
      • Wroclaw, Dolnoslaskie, Polska, 50-367
        • Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
      • Wroclaw, Dolnoslaskie, Polska, 53-439
        • Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku
    • Lodzkie
      • Lódz, Lodzkie, Polska, 93-510
        • Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika
    • Mazowieckie
      • Warszawa, Mazowieckie, Polska, 02-776
        • Instytut Hematologii i Transfuzjologii
    • Slaskie
      • Katowice, Slaskie, Polska, 40-032
        • Samodzielny Publiczny SK im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach
  • Republika Korei
      • Daegu, Republika Korei, 700-721
        • Kyungpook National University Hospital
      • Seoul, Republika Korei, 138-736
        • Asan Medical Center
      • Seoul, Republika Korei, 152-703
        • Korea University Hospital at Guro
      • Seoul, Republika Korei, 137-701
        • Seoul Saint Mary's Hospital Seocho-gu
    • Seoul
      • Gangnam-gu, Seoul, Republika Korei, 135-710
        • Samsung Medical Center
      • Jongno-gu, Seoul, Republika Korei, 110-774
        • Seoul National University Hospital
      • Seodaemun-gu, Seoul, Republika Korei, 120-752
        • Yonsei University Health System
  • Stany Zjednoczone
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02115
        • Massachusetts General Hospital
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • MD Anderson Cancer Center
  • Tajwan
      • Taipei, Tajwan, 10002
        • National Taiwan University Hospital
      • Taipei, Tajwan, 11217
        • Taipei Veterans General Hospital Pei-Tou District
    • Kaohsiung
      • Niao-Sung Hsiang, Kaohsiung, Tajwan, 83301
        • Chang Gung Memorial Hospital, Kaohsiung
  • Włochy
      • Alessandria, Włochy, 15121
        • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
      • Ancona, Włochy, 60126
        • Azienda Ospedaliera Universitaria - Ospedali Riuniti di Ancona
      • Bari, Włochy, 70124
        • Azienda Ospedaliera Policlinico Di Bari
      • Bologna, Włochy, 40138
        • Azienda Ospedaliera Sant'Orsola Malpighi
      • Firenze, Włochy, 50134
        • Azienda Ospedaliero-Universitaria Careggi
      • Reggio Calabria, Włochy, 89100
        • Azienda Ospedaliera Bianchi-Melacrino-Morelli
      • Roma, Włochy, 00168
        • Policlinico Universitario Agostino Gemelli
      • Roma, Włochy, 00161
        • Azienda Policlinico Umberto I di Roma
      • Udine, Włochy, 33100
        • Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine
      • Varese, Włochy, 21100
        • Ospedale di Circolo e Fondazione Macchi
    • Potenza
      • Rionero in Vulture, Potenza, Włochy, 85028
        • IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
    • Turin
      • Orbassano, Turin, Włochy, 10043
        • Azienda Sanitaria Ospedaliera "San Luigi Gonzaga"
  • Zjednoczone Królestwo
      • Bournemouth, Zjednoczone Królestwo, BH7 7DW
        • Royal Bournemouth Hospital
      • London, Zjednoczone Królestwo, SE5 9RS
        • King's College Hospital
      • London, Zjednoczone Królestwo, EC1A 7BE
        • Barts and the London NHS Trust
      • Manchester, Zjednoczone Królestwo, M13 9WL
        • Manchester Royal Infirmary
      • Oxford, Zjednoczone Królestwo, OX3 9DS
        • Churchill Hospital
      • Wolverhampton, Zjednoczone Królestwo, WV10 0QP
        • New Cross Hospital
    • Surrey
      • Sutton, Surrey, Zjednoczone Królestwo, SM2 5PT
        • Royal Marsden Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

65 lat i starsze (Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Diagnosis of one of the following

    • Newly diagnosed de novo acute myeloid leukemia (AML)
    • AML secondary to myelodysplastic syndromes (MDS)
    • AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years
  • Bone marrow blasts >30%
  • Age ≥ 65 years
  • Easter Cooperative Oncology Group (ECOG) 0-2

Exclusion Criteria:

  • Previous cytotoxic or biologic treatment for AML (except hydroxyurea)
  • Previous treatment with azacitidine, decitabine or cytarabine
  • Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors)
  • AML French American British subtype (FAB M3)
  • AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes
  • Prior bone marrow or stem cell transplantation
  • Candidate for allogeneic bone marrow or stem cell transplant
  • Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)
  • Malignant hepatic tumors
  • Uncontrolled systemic infection
  • Active viral infection with Human Immunodeficiency Virus (HIV) or Hepatitis type B or C
  • Use of any experimental drug or therapy within 28 days prior to Day 1

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Azacitidine
Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
Lek: Azacitidine
75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
Inne nazwy:
  • Vidaza
Aktywny komparator: Conventional Care Regimen
Lek: Conventional Care Regimen

Physician pre-selects prior to randomization from one of the following:

  • Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles
  • Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity
  • Best Supportive Care only; until study end

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Kaplan-Meier Estimates for Overall Survival
Ramy czasowe: Day 1 (randomization) to 40 months
Overall Survival was defined as the time from randomization to death from any cause. Overall survival was calculated by the formula: date of death - date of randomization + 1. Participants surviving at the end of the follow-up period or who withdrew consent to follow-up were censored at the date of last contact. Participants who were lost to follow-up were censored at the date last known alive.
Day 1 (randomization) to 40 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
One-year Overall Survival Rate
Ramy czasowe: From Day 1 (randomization) to 40 months
Kaplan Meier methods were used to estimate the 1-year survival probabilities for time to death from any cause. Estimates of the 1-year (365 day) survival probabilities and corresponding 95% confidence intervals (CI) were presented by treatment group. The CI for the difference in the 1-year survival probabilities was derived using Greenwoods variance estimate.
From Day 1 (randomization) to 40 months
Event-free Survival (EFS)
Ramy czasowe: Day 1 (randomization) to date of treatment failure, progressive disease, relapse after Complete Remission (CR) or Complete remission with incomplete blood count recovery (CRi), death from any cause. Day 1 (randomization) to 40 months
Event-free survival was defined as the interval from the date of randomization to the date of treatment failure, progressive disease, relapse after complete remission (CR) or complete remission with incomplete blood count recovery (CRi), death from any cause, or lost to follow-up, whichever occurs first. Participants who were still alive without any of these events were censored at the date of their last response assessment.
Day 1 (randomization) to date of treatment failure, progressive disease, relapse after Complete Remission (CR) or Complete remission with incomplete blood count recovery (CRi), death from any cause. Day 1 (randomization) to 40 months
Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
Ramy czasowe: Day 1 of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up. Day 1 (randomization) to 40 months
Relapse-free survival was defined as the interval from the date of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up, whichever occurred first. Participants who were still alive and in continuous CR or CRi were censored at the date of their last response assessment.
Day 1 of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up. Day 1 (randomization) to 40 months
Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)
Ramy czasowe: Day 1 (randomization) to 40 months
A complete remission (CR) is defined as a leukemia-free state defined as less than 5% blasts in a BM aspirate with marrow spicules and with at least 200 nucleated cells (there should be no blasts with Auer rods), an absolute neutrophil count (ANC) of ≥ 1 x 10^9/L, a platelet count ≥ 100 x 10^9/L, and transfusion independence (no transfusions for 1 week prior to each assessment). No duration of these findings is required for confirmation of this response. A CR with incomplete blood count recovery (CRi) is defined as <5% BM blasts with the ANC count < 1 x 10^9/L and/or the platelet count may be < 100 x 10^9/L. Where the date of the hematology assessment used is the earliest on or following the date of the BM sample up to 8 days after the BM date.
Day 1 (randomization) to 40 months
Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates
Ramy czasowe: Day 1 (randomization) to 40 months; date of the first documented CR or CRi until date of first documented relapse.
The time from the date CR or CRi was first documented until the date of documented relapse from CR/CRi. Duration of remission was defined only for those participants who achieved a CR or CRi, as determined by the IRC. Participants who were lost to follow-up without documented relapse, or were alive at last follow-up without documented relapse were censored at the date of their last response assessment.
Day 1 (randomization) to 40 months; date of the first documented CR or CRi until date of first documented relapse.
Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.
Ramy czasowe: Day 1 (randomization) to 40 months
The CRc is a normal karyotype defined as no clonal abnormalities after review of at least 10 metaphases using conventional cytogenetic techniques. Cytogenetic complete remission rate (CRc) is when the following criteria are met: 1) CR criteria met and 2) an abnormal karyotype is present at baseline and 3) there is reversion to normal karyotype at the time of CR (based on ≥ 10 metaphases), where date of cytogenetic sample = date of BM sample used for the CR assessment
Day 1 (randomization) to 40 months
Number of Participants With Adverse Events (AEs)
Ramy czasowe: Day 1 (randomization) up to last visit completed; final data cut off of 28 Feb 2017
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
Day 1 (randomization) up to last visit completed; final data cut off of 28 Feb 2017
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
Ramy czasowe: Baseline to Cycle 3; at approximately 3 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).
Baseline to Cycle 3; at approximately 3 months
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
Ramy czasowe: Baseline to Cycle 5, at approximately 5 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).
Baseline to Cycle 5, at approximately 5 months
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
Ramy czasowe: Baseline to Cycle 7, at approximately 7 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).
Baseline to Cycle 7, at approximately 7 months
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
Ramy czasowe: Baseline to Cycle 9, at approximately 9 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).
Baseline to Cycle 9, at approximately 9 months
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
Ramy czasowe: Baseline to End of Study; at approximately 11-12 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).
Baseline to End of Study; at approximately 11-12 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
Ramy czasowe: Baseline to Cycle 3, at approximately 3 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).
Baseline to Cycle 3, at approximately 3 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
Ramy czasowe: Baseline to Cycle 5, at approximately 5 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).
Baseline to Cycle 5, at approximately 5 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
Ramy czasowe: Baseline to Cycle 7, at approximately 7 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).
Baseline to Cycle 7, at approximately 7 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
Ramy czasowe: Baseline to Cycle 9, at approximately 9 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).
Baseline to Cycle 9, at approximately 9 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
Ramy czasowe: Baseline to end of study, at approximately 11-12 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).
Baseline to end of study, at approximately 11-12 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
Ramy czasowe: Baseline to Cycle 3, at approximately 3 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Baseline to Cycle 3, at approximately 3 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
Ramy czasowe: Baseline to Cycle 5, at approximately 5 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Baseline to Cycle 5, at approximately 5 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
Ramy czasowe: Baseline to Cycle 7, at approximately 7 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Baseline to Cycle 7, at approximately 7 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
Ramy czasowe: Baseline to Cycle 9, at approximately 9 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Baseline to Cycle 9, at approximately 9 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
Ramy czasowe: Baseline to end of study, at approximately 11-12 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Baseline to end of study, at approximately 11-12 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
Ramy czasowe: Baseline to Cycle 3, at approximately 3 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.
Baseline to Cycle 3, at approximately 3 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
Ramy czasowe: Baseline to Cycle 5, at approximately 5 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.
Baseline to Cycle 5, at approximately 5 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
Ramy czasowe: Baseline to Cycle 7, at approximately 7 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.
Baseline to Cycle 7, at approximately 7 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
Ramy czasowe: Baseline to Cycle 9, at approximately 9 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.
Baseline to Cycle 9, at approximately 9 months
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
Ramy czasowe: Baseline to end of study, at approximately 11-12 months
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.
Baseline to end of study, at approximately 11-12 months
Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations
Ramy czasowe: Day 1 (randomization) to 40 months
HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.
Day 1 (randomization) to 40 months
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year
Ramy czasowe: Day 1 (randomization) to 40 months
HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.
Day 1 (randomization) to 40 months
HRU: Number of Participants Receiving Transfusions
Ramy czasowe: Day 1 (randomization) to 40 months
Count of study participants who had transfusions during the treatment phase. HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.
Day 1 (randomization) to 40 months
HRU: Rate of Transfusions Per Patient Year
Ramy czasowe: Day 1 (randomization) to 40 months
HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of transfusions per patient year was calculated as the total number of transfusions divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.
Day 1 (randomization) to 40 months
Number of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)
Ramy czasowe: From the date of informed consent for the Extension Phase through to the date of last dose of study drug + 28 days up to last visit completed 24 July 2016; maximum duration of exposure to Azacitidine was 871 days
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
From the date of informed consent for the Extension Phase through to the date of last dose of study drug + 28 days up to last visit completed 24 July 2016; maximum duration of exposure to Azacitidine was 871 days

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Celgene

Śledczy

  • Dyrektor Studium: C L Beach, PharmD, Celgene Corporation

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 czerwca 2010

Zakończenie podstawowe (Rzeczywisty)

22 stycznia 2014

Ukończenie studiów (Rzeczywisty)

25 lipca 2016

Daty rejestracji na studia

Pierwszy przesłany

16 lutego 2010

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 lutego 2010

Pierwszy wysłany (Oszacować)

24 lutego 2010

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

29 sierpnia 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

25 sierpnia 2017

Ostatnia weryfikacja

1 sierpnia 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • AZA-AML-001

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Ostra białaczka szpikowa

Badania kliniczne na Azacitidine

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Cambodia

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj